Xaluprine (previously Mercaptopurine Nova Laboratories)
mercaptopurine · Lipomed GmbH
AUTHORISED IN THE EUWhat Xaluprine (previously Mercaptopurine Nova Laboratories) is used for
Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Xaluprine (previously Mercaptopurine Nova Laboratories)
- Active substance
- mercaptopurine
- Disease area
- Leukemia, Lymphoid
- Medicine group
- Antineoplastic agents
- ATC code
- L01BB02
- Marketing authorisation holder
- Lipomed GmbH
- Authorised in the EU since
- 2012
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Xaluprine (previously Mercaptopurine Nova Laboratories) used for?
Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
What is the active substance in Xaluprine (previously Mercaptopurine Nova Laboratories)?
Xaluprine (previously Mercaptopurine Nova Laboratories) contains mercaptopurine.
Who makes Xaluprine (previously Mercaptopurine Nova Laboratories)?
The EU marketing authorisation holder is Lipomed GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU